{
    "clinical_study": {
        "@rank": "1651", 
        "arm_group": [
            {
                "arm_group_label": "Genotypes 1 or 4", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotypes 1 or 4 HCV infection will receive LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "Genotype 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 2 HCV infection will receive sofosbuvir plus ribavirin for 12 weeks."
            }, 
            {
                "arm_group_label": "Genotype 3", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic genotype 3 HCV infection will receive sofosbuvir plus ribavirin for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the HCV antiviral efficacy, safety, and tolerability of treatment\n      with Ledipasvir/Sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for participants with\n      genotypes 1 and 4 HCV infection and Sofosbuvir (SOF) + Ribavirin (RBV) for participants with\n      genotypes 2 and 3 HCV infection. Participants with an inherited bleeding disorder and\n      chronic HCV infection (either monoinfected or HIV-1/HCV coinfected) will be enrolled."
        }, 
        "brief_title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemorrhage", 
                "Hepatitis", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hemophilia A, B or C, or Von Willebrand's disease\n\n          -  Chronic genotype 1, 2, 3 or 4 HCV infection\n\n          -  HCV RNA \u2265 1000 IU/mL at screening\n\n          -  Use of protocol specified method(s) of contraception if female of childbearing\n             potential or sexually active male\n\n          -  Screening laboratory values within defined thresholds\n\n          -  For HIV-1/HCV co-infected subjects:\n\n               -  Suppressed HIV-1 RNA on an antiretroviral (ARV) regimen for at least 6 months\n                  prior to screening\n\n               -  Stable protocol-approved ARV regimen for > 8 weeks prior to screening\n\n               -  CD4 T-cell count > 200 cells/mm^3 at screening\n\n        Exclusion Criteria:\n\n          -  Clinically-significant illness (other than HCV, inherited bleeding disorder or HIV-1)\n             or any other major medical disorder that may interfere with subject treatment,\n             assessment or compliance with the protocol\n\n          -  Current or prior history of any of the following:\n\n               -  Hepatic decompensation\n\n               -  Chronic liver disease of a non-HCV etiology\n\n               -  Hepatocellular carcinoma (HCC)\n\n               -  Infection with hepatitis B virus (HBV)\n\n          -  Pregnant or nursing female\n\n          -  Prior treatment with inhibitors of NS5A or the NS5B polymerase\n\n          -  Chronic use of systemically administered immunosuppressive agents\n\n          -  For HIV-1/HCV co-infected subjects:\n\n               -  Opportunistic infection within 6 months prior to screening\n\n               -  Active, serious infection (other than HIV-1 or HCV) requiring parental\n                  antibiotics, antivirals or antifungals within 30 days prior to baseline"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120300", 
            "org_study_id": "GS-US-334-1274"
        }, 
        "intervention": [
            {
                "arm_group_label": "Genotypes 1 or 4", 
                "description": "LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily", 
                "intervention_name": "LDV/SOF", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "GS-5885"
                ]
            }, 
            {
                "arm_group_label": [
                    "Genotype 2", 
                    "Genotype 3"
                ], 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sovaldi\u00ae", 
                    "GS-7977", 
                    "PSI-7977"
                ]
            }, 
            {
                "arm_group_label": [
                    "Genotype 2", 
                    "Genotype 3"
                ], 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103-8651"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55407"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07112"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14621"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-7584"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders", 
        "overall_contact": {
            "email": "334-1274alerts@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Luisa Stamm, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 is defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 4"
            }, 
            {
                "measure": "Proportion of participants with HCV RNA < LLOQ on treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "HCV RNA change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }, 
            {
                "description": "Virologic failure is defined as:\nBreakthrough: HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ, while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values, OR\nRebound: > 1 log10IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow up values, OR\nNonresponse: HCV RNA persistently \u2265 LLOQ through 8 weeks of treatment, OR\nRelapse: HCV RNA \u2265 LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement", 
                "measure": "Proportion of participants with virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to posttreatment Week 12"
            }, 
            {
                "measure": "For HIV-1/HCV co-infected participants, the proportion of subjects that maintain HIV-1 RNA < 50 copies/mL while on HCV treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 24"
            }, 
            {
                "measure": "For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at posttreatment Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline to posttreatment Week 12"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}